losartan has been researched along with Adenocarcinoma in 6 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Adenocarcinoma: A malignant epithelial tumor with a glandular organization.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with gemcitabine plus losartan further prolonged the survival time to 102." | 5.40 | Antitumor effect of angiotensin II type 1 receptor blocker losartan for orthotopic rat pancreatic adenocarcinoma. ( Hirooka, S; Inoue, K; Kim, S; Kwon, AH; Matsui, Y; Satoi, S; Toyokawa, H; Yamaki, S; Yamamoto, T; Yamao, J; Yanagimoto, H, 2014) |
| "Angiotensin II (AngII), the principal hormone of the renin-angiotensin system, is actively generated in the pancreas and has been proposed as a key mediator of inflammation." | 3.75 | Angiotensin II regulates the expression of monocyte chemoattractant protein-1 in pancreatic cancer cells. ( Arafat, HA; Aziz, T; Chehl, N; Chipitsyna, G; Gong, Q; Yeo, CJ, 2009) |
| "Losartan treatment prevented tumor-induced loss of muscle mass and in vitro c26 cell proliferation, decreased tumor weight, and attenuated myocardial expression of interleukin-6." | 1.42 | Losartan treatment attenuates tumor-induced myocardial dysfunction. ( Bicer, S; Clark, Y; Devine, RD; Jing, R; McCarthy, DO; Reiser, PJ; Stevens, SC; Velten, M; Wold, LE; Youtz, DJ, 2015) |
| "Treatment with gemcitabine plus losartan further prolonged the survival time to 102." | 1.40 | Antitumor effect of angiotensin II type 1 receptor blocker losartan for orthotopic rat pancreatic adenocarcinoma. ( Hirooka, S; Inoue, K; Kim, S; Kwon, AH; Matsui, Y; Satoi, S; Toyokawa, H; Yamaki, S; Yamamoto, T; Yamao, J; Yanagimoto, H, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Das, M | 1 |
| Kocyigit, I | 1 |
| Dortdudak, S | 1 |
| Eroglu, E | 1 |
| Unal, A | 1 |
| Sipahioglu, MH | 1 |
| Berk, V | 1 |
| Tokgoz, B | 1 |
| Oymak, O | 1 |
| Kim, S | 1 |
| Toyokawa, H | 1 |
| Yamao, J | 1 |
| Satoi, S | 1 |
| Yanagimoto, H | 1 |
| Yamamoto, T | 1 |
| Hirooka, S | 1 |
| Yamaki, S | 1 |
| Inoue, K | 1 |
| Matsui, Y | 1 |
| Kwon, AH | 1 |
| Stevens, SC | 1 |
| Velten, M | 1 |
| Youtz, DJ | 1 |
| Clark, Y | 1 |
| Jing, R | 1 |
| Reiser, PJ | 1 |
| Bicer, S | 1 |
| Devine, RD | 1 |
| McCarthy, DO | 1 |
| Wold, LE | 1 |
| Chehl, N | 1 |
| Gong, Q | 1 |
| Chipitsyna, G | 1 |
| Aziz, T | 1 |
| Yeo, CJ | 1 |
| Arafat, HA | 1 |
| Papp, M | 1 |
| Li, X | 1 |
| Zhuang, J | 1 |
| Wang, R | 1 |
| Uhal, BD | 1 |
6 other studies available for losartan and Adenocarcinoma
| Article | Year |
|---|---|
Combined treatment for locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Antihypertensive Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2019 |
Immunoglobulin A nephropathy could be a clue for the recurrence of gastric adenocarcinoma.
Topics: Adenocarcinoma; Bone Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Edema; Glomerulonephri | 2013 |
Antitumor effect of angiotensin II type 1 receptor blocker losartan for orthotopic rat pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Angiotensin II Type 1 Receptor Blockers; Animals; Antineoplastic Combined Chemothera | 2014 |
Losartan treatment attenuates tumor-induced myocardial dysfunction.
Topics: Adenocarcinoma; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Calcium Signaling; | 2015 |
Angiotensin II regulates the expression of monocyte chemoattractant protein-1 in pancreatic cancer cells.
Topics: Adenocarcinoma; Angiotensin II; Blotting, Western; Cell Line, Tumor; Chemokine CCL2; Extracellular S | 2009 |
Angiotensin receptor subtype AT(1) mediates alveolar epithelial cell apoptosis in response to ANG II.
Topics: Adenocarcinoma; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Apoptosis | 2002 |